Alimera Resubmits Iluvien In U.S. As It Begins EU Launch
This article was originally published in The Pink Sheet Daily
The Atlanta-based ophthalmology company hopes to succeed in third try with FDA, but must split its focus with Europe as it tries to roll out launches in several countries at once.
You may also be interested in...
U.S. Biotechs Strike Out Across Europe
U.S. biotech companies are showing greater interest in building commercial infrastructure in Europe, in order to bring new medicines to European customers without local partners. Switzerland is a popular location, because of its position in the center of the continent, but the presence of experienced management is also important.
Market Snapshot: Diabetic Macular Edema, Another Blockbuster Opportunity For Retinal Drugs?
Having relatively rapidly built a multi-billion dollar market in wet age-related macular degeneration, biotech and pharma companies may be about to repeat the exercise with diabetic macular edema, a complication of diabetes that’s growing in importance as the population ages and the disease spreads.
NICE Clears Alimera’s Iluvien For DME In Patients With Artificial Lens
Alimera Sciences’s Iluvien gets reimbursement clearance in the U.K. for diabetic macular edema patients unresponsive to other therapies with the help of a price discount and the lack of cataract side effects by limiting its use to patients with artificial lens.